Edwards Lifesciences Corp (NYSE:EW) reported its fourth-quarter financial results, delivering a mixed performance against analyst expectations. The structural heart device leader posted strong sales growth but fell short on profitability, a dynamic reflected in the stock's immediate after-hours trading.
Fourth Quarter Performance vs. Estimates
The company reported Q4 2025 sales of $1.57 billion, representing a solid 13.3% year-over-year increase. However, this figure came in slightly below the analyst consensus estimate of approximately $1.59 billion. The core earnings story was more pronounced. Edwards reported adjusted earnings per share (EPS) of $0.58 for the quarter, which missed the Wall Street estimate of $0.64.
The variance in EPS can be attributed to several factors evident in the financial statements:
- A significant increase in selling, general, and administrative (SG&A) expenses, which rose to 38.4% of sales from 35.5% a year ago. The company noted this funded strategic investments to amplify patient access to therapies.
- A higher-than-expected tax rate for the quarter.
- Substantial intellectual property litigation and related expenses, which totaled $208.6 million in Q4 compared to $12.6 million in the prior year period.
Market Reaction and Forward Guidance
Following the earnings release, Edwards Lifesciences shares saw a positive move in after-market trading, rising approximately 1.9%. This suggests investors may be looking beyond the quarterly EPS miss and focusing on the company's sustained sales growth and confident outlook for 2026.
Management expressed increased confidence in its full-year 2026 guidance, projecting constant currency sales growth of 8% to 10% and adjusted EPS in the range of $2.90 to $3.05. This EPS outlook brackets the current analyst consensus estimate of $2.97 for the year. For the first quarter of 2026, the company expects sales between $1.55 billion and $1.63 billion and adjusted EPS of $0.70 to $0.76, compared to analyst estimates of $1.62 billion in sales and $0.76 in EPS.
Key Business Segment Highlights
The earnings report underscored the company's momentum across its portfolio:
- Transcatheter Aortic Valve Replacement (TAVR): Sales grew 12.0% to $1.16 billion. The company highlighted stable global pricing and competitive position, healthy procedure growth in Europe, and the potential for improved patient access in the U.S. as CMS reconsiders the National Coverage Determination for TAVR.
- Transcatheter Mitral and Tricuspid Therapies (TMTT): This high-growth segment saw sales surge more than 40% to $156 million, driven by global adoption of the PASCAL repair and EVOQUE replacement systems. The recent U.S. FDA approval of the SAPIEN M3 system, the first transcatheter mitral replacement option, adds another layer to this portfolio.
- Surgical Structural Heart: Sales increased 4% to $254 million, supported by adoption of the company's RESILIA tissue technology.
Financial Position and Margins
Edwards ended the year with a strong balance sheet, holding approximately $3.0 billion in cash and cash equivalents against $600 million in debt. The adjusted gross profit margin for Q4 was 78.3%, and the company expects its full-year 2026 adjusted gross profit margin to remain between 78% and 79%. Research and development spending is anticipated to be approximately 17% of sales for the year.
Conclusion
Edwards Lifesciences concluded 2025 with robust sales growth, particularly in its emerging TMTT franchise, but faced profitability headwinds from strategic investments and litigation costs. The market's initial positive reaction indicates a focus on the company's reaffirmed growth trajectory and its positioning within the large and growing structural heart market. The success of new product launches like SAPIEN M3 and the continued scaling of TMTT therapies will be critical to meeting its ambitious 2026 targets.
For a detailed look at historical earnings and future analyst estimates for Edwards Lifesciences, visit the earnings and estimates page.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation to buy or sell any security, or an endorsement of any investment strategy. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.